Keyword: Pear Therapeutics
Pear Therapeutics' prescription apps for substance abuse are designed to not only complement medication-assisted treatments but also reproduce the effects of face-to-face psychology sessions.
Pear Therapeutics and Novartis’ new digital treatment is designed to be given alongside a disease-modifying therapy for relapsing multiple sclerosis.
Pear Therapeutics aims to develop digital therapeutics that reproduce the changes seen in a patient’s neural circuitry following traditional, face-to-face sessions of cognitive behavioral therapy.
These are the ideas that can move the needle. FierceMedTech’s Fierce 15 class of 2018 is aimed at advancement—whether it’s simply combining new know-how with old methods, making definitive improvements in well-trodden fields, or pushing us to reconsider how far we can reach with the means available today.
Pear Therapeutics posted $64 million in new funding on the heels of an FDA clearance for its prescription software to treat opioid addiction.
The agreement sees Novartis work with Pear to get a schizophrenia app to market while developing an earlier-stage treatment for multiple sclerosis.
The series B sets Pear up to market its recently approved substance-use disorder app while working to bring follow-up digital therapies to market.